Article Text

Download PDFPDF
Budd-Chiari syndrome after BNT162b2 mRNA vaccination: two case reports
  1. Lorene Lipszyc1,
  2. Louise Triquet2,
  3. Baptiste Giguet3,
  4. Olivier Lambotte4,
  5. Samy Babai1
    1. 1Department of Pharmacovigilance, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Henri Mondor, Creteil, France
    2. 2Regional Pharmacovigilance Center, CHU de Rennes, Rennes, Bretagne, France
    3. 3Liver disease department, CHU de Rennes, Rennes, Bretagne, France
    4. 4Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Bicetre, Le Kremlin-Bicetre, Ile-de-France, France
    1. Correspondence to Dr Lorene Lipszyc, Department of Pharmacovigilance, Assistance Publique-Hôpitaux de Paris (AP-HP), CHU Henri Mondor, Creteil, France; lorene.lipszyc{at}aphp.fr

    Abstract

    Budd-Chiari syndrome (BCS) is a rare disease characterised by an obstruction in the hepatic venous outflow. We describe two cases of patients hospitalised a few days after tozinameran vaccination. Liver tests and medical imaging were carried out, and BCS was diagnosed. After treatment including anticoagulant therapy, the first patient improved clinically, unlike the second patient with persistent hepatic thrombosis. According to the WHO-UMC causality assessment system, the vaccine’s share was assessed as ‘probable’ for the first patient as BCS occurred during anticoagulant therapy, and ‘possible’ for the second patient as no other aetiology was found. Further epidemiological studies are needed to confirm or refute the causal relationship between BCS and tozinameran vaccination.

    • COVID-19
    • Adverse Drug Reaction Reporting Systems
    • Pharmacovigilance
    • Immunization
    • Case Reports

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplementary information.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplementary information.

    View Full Text